MLi-2 is a leucine-rich repeat kinase 2 (LRRK2) inhibitor and may be used in the treatment and prevention of Parkinsons disease as its a precursor to the illness. A brain-penetrant inhibitor of leucin-rich repeat kinase 2 (LRRK2) with IC50 = 0.76nM and anti-parkinsonian activity. Gain-of-function mutations in LRRK2 gene lead to increased familial and idiopathic risk of developing the disease. The inhibitors of the kinase activity have therapeutic potential against Parkinsons disease. Synonyms: rel-3-[6-[(2R,6S)-2,6-Dimethyl-4-morpholinyl]-4-pyrimidyl]-5-[(1-methylcyclopropyl)oxy]-1H-indazole CAS No: 1627091-47-7 Molecular Formula: C21H25N5O2 Molecular Weight: 379.46 Appearance: White to off-white powder Purity: 98% Identity (1H NMR): Conforms to structure Elemental analysis (C,H,N) (on dry basis): C: 66.07-66.87%, H: 6.24-7.04%, O:18.06-18.86% Biological Activity: Potent and selective LRRK2 inhibitor (IC50 = 0.76-3.4nM depending on assay). Exhibits >295-fold selectivity for over 300 kinases and a diverse panel of receptors and ion channels. Centrally bioavailable and active in vivo. Solubility: DMSO, 50mM Storage and Stability: Store at -20C. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Molekulargewicht:
379.46
Reinheit:
98%
Formulierung:
White to off-white powder
CAS Nummer:
[1627091-47-7]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
